Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.
| Quarter | Action | Shares change | Est. value change | Δ Own | Shares held | Filing date |
|---|---|---|---|---|---|---|
| Q2 2023 | Exited | −1.5M | – | −100.0% | 0 | Aug 11, 2023 |
| Q1 2023 | New | +1.5M | – | – | 1.5M | May 12, 2023 |
| Q2 2022 | New | +768K | – | – | 768K | Aug 12, 2022 |
| Q2 2021 | Reduced | −119K | – | −21.1% | 444K | Aug 13, 2021 |
| Q1 2021 | First covered | – | – | – | 562K | May 13, 2021 |
Not currently. Jim Simons fully exited DBD in Q2 2023, and the complete history is above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Jim Simons held DBD since at least Q1 2021, when this filing coverage begins; the opening snapshot is not a disclosed purchase. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Yes. Jim Simons reduced and then fully exited DBD by Q2 2023; the reductions are in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
None as of the latest filing: Jim Simons has exited DBD. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Jim Simons began building the DBD position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
